Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Microcalorimeter

By Drug Discovery Trends Editor | January 16, 2009

MicroCal introduced the latest advance in Isothermal Titration Calorimetery (ITC), the Auto-iTC200, which is designed to address the needs of today’s life science researchers – particularly those in drug discovery and development.

The system combines the performance of the ultra-sensitive iTC200 with full automation to run of up to 75 samples per day. The Auto-iTC200 enables the determination of all binding parameters in a single experiment, label-free and without the need for immobilization, using as little as five-10 ?g of protein per experiment. This system provides scientists with a powerful tool to develop new drugs without the limitations imposed by traditional assay systems, which often lack biological relevance, according to MicroCal.

The Auto-iTC200 is fully automated with all functions operated through software which includes integrated design wizards to assist in selecting experimental run parameters. Fully automated post-run data analysis utilizes Origin. Results are also exported in Microsoft Excel format for further analysis or data transfer. A wide range of applications can be accomplished with the Auto-iTC200 including: characterization of molecular interactions of small molecules, proteins, antibodies, nucleic acids, lipids and other biomolecules, enzyme kinetics, assessing the effects of molecular structure changes on binding mechanisms (SAR), and biotherapeutic construct selection.

www.microcal.com


Filed Under: Drug Discovery

 

Related Articles Read More >

TransCelerate CEO Janice Chang wants trials to become part of routine care
STEERLife’s FragMelt platform manufactures drugs with heat sensitive active ingredient 
S&P report highlights Big Pharma’s concentration risk amid pre-JPM deal flurry
Eli Lilly in the Drug Discovery & Development Pharma 50
Lilly Phase 3b trial shows roughly 40-fold higher combined arthritis and weight-loss response
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2026 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE